Altered trimethoprim-sulfamethoxazole ratios for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii dual infections in rat model

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue 3, 1996, Pages 201-207

  Brun Pascaud, Monique ^a   Chau, Françoise ^a   Garry, Louis ^a   Farinotti, Robert ^a   Derouin, Francis ^b   Girard, Pierre Marie ^a,c  

^a BICHAT HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL ROTHSCHILD   (France)

Author keywords

Pneumocystis carinii pneumonia; Sulfamethoxazole; Toxoplasma gondii; Trimethoprim

Indexed keywords

COTRIMOXAZOLE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAT; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; PNEUMOCYSTIS CARINII; TOXOPLASMA GONDII;

EID: 0029959303     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199611010-00001     Document Type: Article

References (30)

1. Masur H. Prevention and treatment of Pneumocystis pneumonia.N Engl J Med 1992;327:1853-60.
2. Carr A, Tindall B, Brew BJ, Marriott DJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmosis encephalitis in patients with AIDS. Ann Intern Med 1992;117:106-11.
3. Brumfitt W, Hamilton-Miller JTM. Reassessment of the rationale for the combinations of sulfonamides with diaminopyrimidines. J Chemother 1993;5:465-9.
4. Zinner SH, Mayer H. Sulfonamides and trimethoprim. In: Mandel GL, Douglas RG, Bennett JE, eds. Principles and practice of infectious diseases. New York: John Wiley and Sons, 1994:354-64.
5. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495-9.
6. Jaffe HS, Abrams DI, Amman AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983;2:1109-11.
7. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984;100:663-71.
8. Mitsuyasu R, Groopman J, Volberding P. Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma. N Engl J Med 1983;308: 1535-6.
9. Koopmans PP, Van der Ven AJ, Vree TB, Van der Meer JWM. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? AIDS 1995;9: 217-22.
10. May T, Beuscart C, Reynes J, et al. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. J Acquir Immune Defic Syndr 1994;7:457-62.
11. Ruskin J, Lariviere M. Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 1991;337:468-71.
12. Wormser GP, Horowitzh HW, Ducanson FP, et al. Low-dose intermittent trimethoprim-sulfamethoxazole for prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. Arch Intern Med 1991;151:688-92.
13. Brun-Pascaud M, Girard PM, Pocidalo JJ. Low-dose trimethoprim-sulfamethoxazole alone and in association with zidovudine for prevention and treatment of murine Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1992;36:2328-30.
14. Hughes WT, Killmar JT, Oz HS. Relative potency of 10 drugs with anti-Pneumocystis carinii activity in aninial model. J Infect Dis 1994;170:906-11.
15. Hughes WT, Smith BL. Intermittent chemoprophylaxis for Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1983;24:300-1.
16. Shear HL, Valladares G, Narachi MA. Enhanced treatment of Pneumocystis carinii pneumonia in rats with interferon-γ and reduced doses of trimethoprim/sulfamethoxazole. J Acquir Immune Defic Syndr 1990;3:943-8.
17. Walzer PD, Foy J, Steele P, White M. Synergic combinations of RO 1-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob Agents Chemother 1993;37:1436-43.
18. Walzer PD, Kim CK, Foy JM, Zhang J. Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1991; 35:158-63.
19. Cushion MT, Stanforth D, Linke MJ, Walzer PD. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vivo. Antimicrob Agents Chemother 1985; 28:796-801.
20. Derouin F, Chastang C. In vitro effect of folate inhibitors on Toxoplasma gondii. Antimicrob Agents Chemother 1989;33: 1753-9.
21. Grossman PL, Remington JS. The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. Am J Trop Med Hyg 1979;28:445-55.
22. Vischer WA. Comparative study of the efficacy of some sulphanilamide derivatives in clinical use against acute toxoplasmosis in the mouse. Zentralblatt Bakteriol Hyg [A] 1973;223:398-408.
23. Brun-Pascaud M, Chau F, Simonpoli AM, Girard PM, Derouin F, Pocidalo JJ. Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis. J Infect Dis 1994;170:653-8.
24. Piketty C, Derouin F, Rouveix B, Pocidalo JJ. In vivo assessment of antimicrobial agents against T. gondii: quantification of parasites in blood, lungs and brain of infected mice. Antimicrob Agents Chemother 1990;34:1467-72.
25. Hughes TH, McNabb PC, Makres TD, Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother 1974;5:;289-93.
26. 4-acetylsulfamethoxazole in body fluids. J Chromatogr 1983;278:337-415.
27. Remington JS. Trimethoprim-sulfamethoxazole in murine toxoplasmosis. Antimicrob Agents Chemother 1976;9:222-3.
28. Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H. Activity of antifolates against Pneumocystis carinil dihydrofolate reductase and identification of a potent new agent. J Exp Med 1987;165:926-31.
29. Walzer PD, Foy J, Steele P, et al. Activities of antifolate, antiviral and others in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1992;36:1935-42.
30. Comley JC, Mullin RJ, Wolfe LA, Hanlon MH, Ferone R. Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii. Antimicrob Agents Chemother 1991;35:1965-74.